PREDILIFE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.3 EUR | -8.03% |
|
-8.70% | +10.53% |
| 2023 | Predilife: a project accredited by Finance Innovation | CF |
| 2023 | Predilife S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| Sales 2022 | 289K 314K | Sales 2023 * | - | Capitalization | 25.35M 27.56M |
|---|---|---|---|---|---|
| Net income 2022 * | - | Net income 2023 * | - | EV / Sales 2022 | 79.4 x |
| Net cash position 2022 | 3.52M 3.83M | Net cash position 2023 * | - 0 | EV / Sales 2023 * | - |
| P/E ratio 2022 * |
-
| P/E ratio 2023 * |
-
| Employees | 20 |
| Yield 2022 * |
-
| Yield 2023 * |
-
| Free-Float | 92.59% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -8.03% | ||
| 1 week | -8.70% | ||
| Current month | -5.97% | ||
| 3 months | +65.79% | ||
| 6 months | +9.57% | ||
| Current year | +10.53% |
1 week
6.30
6.95
1 month
6.058.50
Current year
3.6024.00
1 year
3.6024.00
3 years
3.6024.00
5 years
3.6024.00
10 years
3.6024.00
| Managers | Title | Age | Since |
|---|---|---|---|
Stéphane Ragusa
CEO | Chief Executive Officer | 53 | 03-12-31 |
Émilien Gauthier
CTO | Chief Tech/Sci/R&D Officer | - | 06-12-31 |
Marion Renelier
LAW | General Counsel | - | 15-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Charles Vilgrain
BRD | Director/Board Member | 44 | 17-12-31 |
Stéphane Ragusa
CEO | Chief Executive Officer | 53 | 03-12-31 |
Antoine Bricard
BRD | Director/Board Member | 56 | 17-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-05 | 6.3 | -8.03% | 1 676 |
| 24-06-04 | 6.85 | +0.74% | 451 |
| 24-06-03 | 6.8 | +1.49% | 85 |
| 24-05-31 | 6.7 | -1.47% | 1,739 |
| 24-05-30 | 6.8 | -1.45% | 633 |
Real-time Euronext Paris, June 05, 2024 at 11:21 am EDT
More quotes
PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women,over 300,000 French women and 500,000 English.
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +10.53% | 27.58M | |
| +17.91% | 3.43B | |
| +2.21% | 2.27B | |
| -19.52% | 2.03B | |
| -20.94% | 1.63B | |
| +31.37% | 1.16B | |
| +18.00% | 714M | |
| -9.39% | 703M | |
| -22.35% | 500M | |
| -1.29% | 279M |
- Stock Market
- Equities
- ALPRE Stock
